# Ark Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ark-biosciences

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.arkbiosciences.com
- Latest round: Series D (Jul 14, 2022)
- Investors on record: 28

## About

Based in Shanghai, China and established in 2014, Ark Biosciences Inc. operates as a biopharmaceutical company that develops drug for the treatment of influenza, hepatitis B and respiratory viruses. The company's founder, Chairman and CEO, Zheng Wu, graduated from Brown University and has over 26 years of experience in drug discovery and development, having served as senior director of Roche China. The company partnered with Calibr in November 2017 to develop a new COPD drug and introduced a new anti-fibrotic drug, AK3280, from Roche in August August 2018. The company has completed 5 rounds of funding as of 2022.

The company's research areas include Respiratory Syncytial Virus (RSV), Idiopathic Pulmonary Fibrosis, Hypertrophic Scars, Chronic Obstructive Pulmonary Disease (COPD) and Hepatitis B. The company's self-developed products include RSV drug Ziresovir, RSV prevention AK0610 and attention deficit hyperactivity disorder drug (ADHD) Azstarys.

## Funding rounds

- Series D, Jul 14, 2022 — Qiming Venture Partners, Oriza Holdings, Oriental Fortune Capital, Loyal Valley Capital, Xiamen C&D Emerging Industry Equity Investment, FTZ Fund, Longda Foodstuff Group Co., Ltd.
- Series C, Jan 22, 2021 — TPG, Qiming Venture Partners, Detong Capital, Oriza Holdings, Oriental Fortune Capital, CITIC Securities, Decheng Capital, DYEE Capital, Yingke Private Equity, Shenzhen Capital Real Estate Fund, Tao Capital, Winfast Holding, FTZ Fund, Yanchuang Capital, Renai Capital, GL Ventures, Kaitou Hanrun Investment, Zhangjiang Torch Investment, Shanghai Boquan Equity Investment Management, Hainan Huayi Venture Capital
- Series B, Oct 13, 2020 — CITIC Securities, Decheng Capital, Yingke Private Equity, Ming Bioventures, FTZ Fund
- Series A, Feb 6, 2017 — Qiming Venture Partners, 5Y Capital, YuanBio Venture, Oriza Ventures
- Series A, Apr 7, 2015 — Qiming Venture Partners, 5Y Capital, TF Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series C, Series D
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- TF Capital — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Oriza Ventures (https://capitalatlas.ai/funds/oriza-ventures) — Series A
- CITIC Securities — Series B, Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B, Series C
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series B, Series C
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series B
- FTZ Fund (https://capitalatlas.ai/funds/ftz-fund) — Series B, Series C, Series D
- TPG (https://capitalatlas.ai/funds/tpg) — Series C
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series C
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series C, Series D
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series C, Series D
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series C
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series C
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series C
- Winfast Holding (https://capitalatlas.ai/funds/winfast-holding) — Series C
- Yanchuang Capital (https://capitalatlas.ai/funds/yanchuang-capital) — Series C
- Renai Capital (https://capitalatlas.ai/funds/renai-capital) — Series C
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series C
- Kaitou Hanrun Investment (https://capitalatlas.ai/funds/kaitou-hanrun-investment) — Series C
- Zhangjiang Torch Investment (https://capitalatlas.ai/funds/zhangjiang-torch-investment) — Series C
- Shanghai Boquan Equity Investment Management — Series C
- Hainan Huayi Venture Capital — Series C
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series D
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series D
- Longda Foodstuff Group Co., Ltd. — Series D